- Home
- POR vs APLS Comparison
POR vs APLS Comparison
Compare POR & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | POR | APLS |
|---|---|---|
| Founded | 1889 | 2009 |
| Country | United States | United States |
| Employees | 2915 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.2B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | POR | APLS |
|---|---|---|
| Price | $51.11 | $40.96 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 21 |
| Target Price | ★ $48.55 | $33.59 |
| AVG Volume (30 Days) | 948.8K | ★ 5.5M |
| Earning Date | 05-01-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.32% | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | ★ 2.77 | 0.20 |
| Revenue | ★ $3,576,000,000.00 | $1,003,782,000.00 |
| Revenue This Year | $6.94 | N/A |
| Revenue Next Year | $5.83 | $18.19 |
| P/E Ratio | ★ $18.46 | $204.80 |
| Revenue Growth | 3.95 | ★ 28.46 |
| 52 Week Low | $39.55 | $16.10 |
| 52 Week High | $54.62 | $41.00 |
Technical Indicators
Market Signals| Indicator | POR | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 86.90 |
| Support Level | $50.29 | $19.29 |
| Resistance Level | $54.39 | N/A |
| Average True Range (ATR) | 0.84 | 0.08 |
| MACD | -0.14 | -0.66 |
| Stochastic Oscillator | 23.79 | 88.57 |
Price Performance
Historical ComparisonAbout POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.6 gigawatts of gas, coal, wind, and hydro generation, along with 300 megawatts of energy storage. In February 2026, PGE proposed acquiring utilities in Washington state from Berkshire Hathaway Energy.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).